British pharmaceutical industry mogul GlaxoSmithKline alongside the French multinational pharmaceutical Sanofi’s vaccine division Sanofi Pasteur said in a joint statement on Friday that the pharma giants had reached an accord with the US Government to supply at least 100 million shots of an experimental pandemic vaccine, while the White House had agreed to lay off up to $2.1 billion for the entire development process of the vaccine including manufacturing, clinical trials, scale-up and deliveries.
Aside from that, Friday’s joint statement of the two European drugmakers had also added that the French pharmaceutical industry titan Sanofi would receive the bulk of the funds, while under the terms of the deal the US Government would be able to receive supply of an additional 500 million doses as a longer-term part of the tie-up.
Nonetheless, the US Government had handed over roughly five billion American Dollars thus far under its Operation Warp Speed Program designed to engineer a vaccine as quickly as possible including a stark total of $472 million sent to Moderna last week.
Aside from that, earlier this week the British Government had cut a deal with a potential vaccine maker for 60 million shots which would be prepared to rollout as early as by the first half of the next year.
GSK-Sanofi DNA vaccine to closely resemble Sanofi’s seasonal flu vaccine
Meanwhile, adding that the pandemic vaccine having been developed by Britain’s GlaxoSmithKline and French Sanofi, would be based on an existing DNA vaccine technology previously used to manufacture Sanofi’s seasonal flu vaccine, Executive Vice President of Sanofi Pasteur, Thomas Triomphe said following reveal of the announcement, “The global need for a vaccine to help prevent COVID-19 is massive, and no single vaccine or company will be able to meet the global demand alone,” while in a jubilant voice, US Health and Human Services Secretary Alex Azar said in a statement, “The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year.
Today’s investment supports the Sanofi and GSK adjuvanted product all the way through clinical trials and manufacturing, with the potential to bring hundreds of millions of safe and effective doses to the American people. ”